首页> 外文期刊>Journal of Molecular Liquids >Aggregation behaviour of tetracaine hydrochloride with Gemini surfactants and the formation of silver nanoparticles using drug-Gemini surfactants mixture
【24h】

Aggregation behaviour of tetracaine hydrochloride with Gemini surfactants and the formation of silver nanoparticles using drug-Gemini surfactants mixture

机译:使用药物 - Gemini表面活性剂混合物与Gemini表面活性剂与Gemini表面活性剂Tetracine盐酸盐的聚集行为及银纳米粒子的形成

获取原文
获取原文并翻译 | 示例
           

摘要

This study aimed to encapsulate drug into the silver nanoparticles (AgNPs) by using drug-Gemini surfactant mixed aggregate. The applicability of drug-surfactant based AgNPs is to carry the maximum amount of drug during the drug delivery process. The nano-size mixed aggregate was prepared by a local anaesthetic amphiphilic drug, tetracaine hydrochloride (TC) and Gemini surfactants, pentamethylene-1, 5-bis(tetradecyldimethylammonium bromide) (GS-5, 14-5-14) and hexamethylene-1,6-bis(tetradecyldimethylammonium bromide) (GS-6, 14-6-14). Surface tension and conductance measurements were used to determine the physiological and thermodynamic interaction parameters of TC-GS-5/GS-6. The negative beta(m) values suggested as the synergistic interactions observed between TC and GS-5/GS-6 mixed aggregate. The TC-GSs mixture was used to stabilizing silver nanoparticles (AgNPs) with a different mole fraction alpha(pi) 0.0-0.99 in aqueous media. The resulting AgNPs characterized by UV-Vis spectroscopy and transmission electron microscopy (TEM). Dynamic light scattering (DLS) suggested that the different types of aggregate formed in aqueous media depending on the internal packing arrangements of TC-GS-5/GS-6. The mole fraction base formulation of drug-surfactant could control the mixed aggregates which could be used to formed drug surfactant based nanoparticles to enhance the performance of drug delivery. (C) 2018 Elsevier B.V. All rights reserved.
机译:该研究旨在通过使用药物 - Gemini表面活性剂混合骨料将药物封装到银纳米颗粒(AgNP)中。基于药物 - 表面活性剂的AgNP的适用性是在药物递送过程中携带最大药物量。纳米尺寸混合骨料通过局部麻醉两亲药物,四氯乙烯(TC)和Gemini表面活性剂,五亚甲基-1,5-双(四酰二甲基溴化铵)(GS-5,14-5-14)和六亚甲基-1 ,6-双(四乙酰二甲基溴化铵)(GS-6,14-6-14)。表面张力和电导测量用于确定TC-GS-5 / GS-6的生理和热力学相互作用参数。作为在Tc和GS-5 / GS-6混合聚集体之间观察到的协同相互作用的负β(m)值。使用Tc-GSS混合物在水性介质中用不同的摩尔分数α(PI)0.0-0.99稳定银纳米颗粒(AgNP)。由uV-Vis光谱和透射电子显微镜(TEM)表征的得到的AgNP。动态光散射(DLS)表明,根据TC-GS-5 / GS-6的内部包装装置,在含水介质中形成的不同类型的聚集体。药物 - 表面活性剂的摩尔级分碱配方可以控制可用于形成基于药物表面活性剂的纳米颗粒的混合聚集体以增强药物递送的性能。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号